The antihypertensive profile of the angiotensin AT1 receptor antagonist, GR138950, and the influence of potential homeostatic compensatory mechanisms in renal hypertensive rats
Open Access
- 1 November 1998
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 125 (6) , 1236-1246
- https://doi.org/10.1038/sj.bjp.0702187
Abstract
The cardiovascular profile of the angiotensin AT1 receptor antagonist, GR138950, and the influence of potential compensatory homeostatic mechanisms on this profile, were investigated in renal artery ligated hypertensive (RALH) rats. GR138950 caused a marked reduction in blood pressure associated with immediate tachycardia in conscious RALH rats. The antihypertensive action of GR138950 appeared biphasic; an immediate fall in blood pressure, which plateaued within 1 h, and which was followed by a further slow decline that reached maximum between 5-7 h after administration. The tachycardia caused by GR138950 was attenuated by atenolol and was abolished by combined pretreatment with atenolol and atropine methyl nitrate. However, the antihypertensive profile of GR138950 was unchanged by these pretreatments. The resting blood pressure and the antihypertensive effect of GR138950, in RALH rats, were unaffected by the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopentamethylene propionyl(1)-O-Me-Tyr2,Arg8]-vasopressin. Thus, vasopressinergic mechanisms are not involved in either maintaining blood pressure in RALH rats, or in compensating for the fall in blood pressure caused by GR138950. In anaesthetized RALH rats, GR138950 caused a marked fall in blood pressure that was accompanied by an increase in heart rate along with sustained increases in renal and splanchnic sympathetic nerve activity. In summary, the biphasic fall in blood pressure evoked by GR138950 in RALH rats can not be explained on the basis of changes in autonomic control of the heart, alteration of vasopressin-mediated vasoconstrictor mechanisms or overall suppression of central sympathetic outflow. Rather, increased vasoconstrictor tone might serve to oppose the initial fall in blood pressure.Keywords
This publication has 32 references indexed in Scilit:
- Investigation of the inhibitory effect of NG-nitro-L-arginine methyl ester on the antihypertensive effect of the angiotensin AT1receptor antagonist, GR138950British Journal of Pharmacology, 1997
- Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemideEuropean Journal of Clinical Pharmacology, 1997
- Losartan, nonpeptide angiotensin II-type 1 (AT1) receptor antagonist, attenuates pressor and sympathoexcitatory responses evoked by angiotensin II andL-glutamate in rostral ventrolateral medullaBrain Research, 1994
- Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1992
- Cardiac haemodynamic effects of the non-peptide, angiotensin II-receptor antagonist, DuP 753, in conscious Long Evans and Brattleboro ratsBritish Journal of Pharmacology, 1991
- Evidence that central 5‐HT1A‐receptors play a role in the von Bezold‐Jarisch reflex in the ratBritish Journal of Pharmacology, 1990
- Differential Anesthetic Depression of Chronotropic Baroreflexes in RatsJournal of Cardiovascular Pharmacology, 1990
- A comparison of the central and peripheral antimuscarinic effects of atropine and methylatropine injected systematically and into the cerebral ventriclesLife Sciences, 1988
- Involvement of vasopressin in cardiovascular regulationCardiovascular Research, 1985
- β-adrenoceptor blocking drugs and hypertensionGeneral Pharmacology: The Vascular System, 1979